GE HealthCare is a global medical technology, pharmaceutical diagnostics, and digital solutions company focused on “precision care” diagnostic imaging systems, ultrasound, patient monitoring/anesthesia equipment, contrast media & radiopharmaceuticals, and clinical/AI software. It operates through four segments that the company reports in investor materials: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

‍

GEHC Stock: What does GE HealthCare do?

GE HealthCare is all about “precision care.” That means combining powerful medical hardware with advanced software and AI to help doctors diagnose, monitor, and treat patients more effectively. The company’s portfolio is vast. Its imaging systems include MRI scanners, CT machines, PET and SPECT scanners, mammography, and X-ray devices. In ultrasound, it offers everything from handheld point-of-care devices to specialized platforms for women’s health and surgical guidance. Through its patient care solutions division, it provides anesthesia machines, ventilators, and patient monitoring systems that are staples in hospitals worldwide. Finally, its pharmaceutical diagnostics business produces contrast media and radiopharmaceuticals agents that make imaging scans more accurate, whether for cancer detection or heart disease evaluation.

‍

GEHC Stock Financial performance
‍

• Market Cap: 33.52B
• Current Price: $73
• Forward P/E: ‪15.03‬
• P/B Ratio: ‪3.44‬
• Debt-to-Equity: ‪1.10‬
• Dividend Yield: 0.19%
• Revenue Growth (Y/Y): 3.47%
• Net Income Growth (Y/Y): 13.55%
• Analyst Upside: +20%

‍

GEHC Stock: Big news and strategic moves

GE HealthCare has been active on the deal-making and partnership front. In early 2025, it signed a seven-year alliance with Sutter Health in California, a partnership that could be worth up to $1 billion. The deal makes GE the exclusive provider of imaging technology and AI solutions across Sutter’s network, ensuring GE equipment and software will be the backbone of its diagnostic services. Around the same time, GE HealthCare struck a £200 million partnership with Nuffield Health in the U.K., agreeing to manage and upgrade nearly 800 diagnostic machines over the next two decades.

On the M&A side, GEHC has been bolstering its software and radiopharma capabilities. It bought MIM Software in 2024, a specialist in advanced medical imaging analytics, and acquired the AI business of Intelligent Ultrasound, strengthening its leadership in ultrasound AI. It also took full control of Nihon Medi-Physics in Japan, a radiopharmaceutical company that supplies tracers for PET and SPECT scans. These deals expand GEHC’s recurring revenue streams and deepen its push into AI-driven and molecular imaging.

Meanwhile, regulators have been supportive of GE’s diagnostic pipeline. In June 2025, the FDA expanded the label for Vizamyl, GE’s PET tracer used in Alzheimer’s diagnosis, widening its use in dementia care pathways.

‍

Recent innovations from GEHC

GE HealthCare’s R&D engine has been firing on all cylinders, with new products launched across MRI, CT, ultrasound, and digital solutions.

In 2024, highlights included the SIGNA Magnus, a head-only 3.0T MRI scanner cleared by the FDA in November, designed specifically for neuroimaging with powerful gradients. The company also expanded Sonic DL, its deep-learning acceleration software, to 3D MRI scans, making brain and spine exams up to 86% faster. In mammography, GE launched Pristina Via, which automates positioning and reduces exam time while using the lowest radiation dose needed. On the digital side, it previewed CareIntellect for Oncology, a generative AI tool that summarizes multimodal patient data to help oncologists track disease progression.

In 2025, the innovation pipeline has stayed strong. The company introduced the Revolution Vibe CT scanner, designed for single-beat cardiac imaging—even in patients with irregular heart rates—making it a powerful tool for cardiology practices. It also unveiled the Freelium MRI magnet, a sealed system that uses less than 1% of the helium needed for conventional MRI, reducing costs and sustainability concerns. In nuclear medicine, the Aurora dual-head SPECT/CT and the AI-powered Clarify DL reconstruction software both received FDA clearance, offering faster, sharper scans. And in surgical ultrasound, the new bkActiv S-series brought AI-driven prostate volume assessment and enhanced imaging for urology and colorectal procedures.

GE HealthCare has positioned itself as more than just a maker of MRI and CT machines. It’s building a portfolio that combines cutting-edge imaging devices, AI-powered software, and critical diagnostic consumables, supported by long-term partnerships with major health systems. Financially, it has proven resilient, managing tariff pressures while still raising profit guidance. On the product side, it continues to roll out meaningful innovations in MRI, CT, ultrasound, and radiopharma that expand its clinical relevance and revenue base.

For investors watching GEHC stock, the story is a mix of steady earnings growth, breakthrough innovations, and a careful balancing act in global markets. With the company leaning hard into AI, digital health, and next-gen imaging hardware, it’s clear that GE HealthCare is positioning itself as one of the key medtech players to watch in 2025 and beyond.

‍

How to find stocks like GEHC stock using AI

GE HealthCare (GEHC) is a perfect example of a stock that moves on events, earnings reports, layoffs, CEO changes, FDA approvals, stock buybacks, dividend increases and more. These are exactly the kinds of catalysts that LevelFields AI scans for in real time.

With LevelFields AI, you don’t need to manually track the endless flow of healthcare news. Instead, the AI surfaces only the events that historically move stock prices, giving you actionable insights right when they happen. That means you can get the right entry point without missing out on profits. You can react quickly, whether you’re trading shares of GEHC stock directly or looking for similar healthcare stocks that respond to regulatory approvals, product innovations, or strategic partnerships.

‍

By combining these AI-driven alerts with options trading strategies, you can turn market-moving healthcare events into profitable opportunities. From identifying which stocks are likely to benefit from the next FDA approval to timing calls or puts around major earnings surprises, LevelFields helps traders cut through the noise and focus on the news that matters most.